GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (XTER:ZEG) » Definitions » Common Stock

AstraZeneca (XTER:ZEG) Common Stock : €371 Mil (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Common Stock?

AstraZeneca's quarterly common stock declined from Jun. 2024 (€360 Mil) to Sep. 2024 (€350 Mil) but then increased from Sep. 2024 (€350 Mil) to Dec. 2024 (€371 Mil).

AstraZeneca's annual common stock declined from Dec. 2022 (€365 Mil) to Dec. 2023 (€356 Mil) but then increased from Dec. 2023 (€356 Mil) to Dec. 2024 (€371 Mil).


AstraZeneca Common Stock Historical Data

The historical data trend for AstraZeneca's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Common Stock Chart

AstraZeneca Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 269.62 342.50 365.33 355.80 370.54

AstraZeneca Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 355.80 356.96 360.45 349.59 370.54

AstraZeneca Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines